Dogra P, Schiavone C, Wang Z, Ruiz-Ramirez J, Caserta S, Staquicini D
JCI Insight. 2023; 8(13.
PMID: 37227783
PMC: 10371350.
DOI: 10.1172/jci.insight.169860.
Dogra P, Schiavone C, Wang Z, Ruiz-Ramirez J, Caserta S, Staquicini D
medRxiv. 2022; .
PMID: 36415468
PMC: 9681049.
DOI: 10.1101/2022.09.14.22279959.
Sherman A, Desjardins M, Baden L
Clin Lab Med. 2022; 42(1):111-128.
PMID: 35153045
PMC: 8563351.
DOI: 10.1016/j.cll.2021.10.008.
Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D
Vaccine. 2021; 40(2):306-315.
PMID: 34933765
PMC: 8673730.
DOI: 10.1016/j.vaccine.2021.12.006.
Callegaro A, Tibaldi F
BMC Med Res Methodol. 2019; 19(1):47.
PMID: 30841856
PMC: 6402125.
DOI: 10.1186/s12874-019-0687-y.
Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease.
Benoit A, Beran J, Devaster J, Esen M, Launay O, Leroux-Roels G
Open Forum Infect Dis. 2015; 2(2):ofv067.
PMID: 26180823
PMC: 4498268.
DOI: 10.1093/ofid/ofv067.
Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.
Angel J, Steele A, Franco M
Hum Vaccin Immunother. 2014; 10(12):3659-71.
PMID: 25483685
PMC: 4514048.
DOI: 10.4161/hv.34361.
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.
Li S, B Gilbert P, Tomaras G, Kijak G, Ferrari G, Thomas R
J Clin Invest. 2014; 124(9):3879-90.
PMID: 25105367
PMC: 4151214.
DOI: 10.1172/JCI75539.
A threshold method for immunological correlates of protection.
Chen X, Bailleux F, Desai K, Qin L, Dunning A
BMC Med Res Methodol. 2013; 13:29.
PMID: 23448322
PMC: 3639076.
DOI: 10.1186/1471-2288-13-29.
Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency.
Cavaliere F, Milito C, Martini H, Schlesier M, Drager R, Schutz K
J Clin Immunol. 2013; 33(4):838-46.
PMID: 23274802
DOI: 10.1007/s10875-012-9856-z.
Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children.
Mikoluc B, Kayhty H, Bernatowska E, Motkowski R
Eur J Clin Microbiol Infect Dis. 2008; 27(10):923-8.
PMID: 18584224
DOI: 10.1007/s10096-008-0523-5.
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
B Gilbert P, Qin L, Self S
Stat Med. 2007; 27(23):4758-78.
PMID: 17979212
PMC: 2646675.
DOI: 10.1002/sim.3122.
Human immunity and the design of multi-component, single target vaccines.
Saul A, Fay M
PLoS One. 2007; 2(9):e850.
PMID: 17786221
PMC: 1952173.
DOI: 10.1371/journal.pone.0000850.
Anti-pneumococcal antibody titre measurement: what useful information does it yield?.
Balmer P, Cant A, Borrow R
J Clin Pathol. 2006; 60(4):345-50.
PMID: 16950855
PMC: 2001126.
DOI: 10.1136/jcp.2006.041210.
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.
Andrews N, Borrow R, Miller E
Clin Diagn Lab Immunol. 2003; 10(5):780-6.
PMID: 12965904
PMC: 193909.
DOI: 10.1128/cdli.10.5.780-786.2003.
